WO2026099147 - SEMAGLUTIDE IN THE TREATMENT OF INTERMITTENT CLAUDICATION
National phase entry is expected:
Publication Number
WO/2026/099147
Publication Date
15.05.2026
International Application No.
PCT/EP2025/081744
International Filing Date
04.11.2025
Title **
[English]
SEMAGLUTIDE IN THE TREATMENT OF INTERMITTENT CLAUDICATION
[French]
SÉMAGLUTIDE POUR LE TRAITEMENT DE LA CLAUDICATION INTERMITTENTE
Applicants **
NOVO NORDISK A/S
Inventors
CATARIG, Andrei-Mircea
RØPCKE, Diana, Mathilde
HOLST, Anders, Gaarsdal
Priority Data
63/716,349
05.11.2024
US
24213241.3
15.11.2024
EP
25167042.8
28.03.2025
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2243 | |
| EPO | Filing, Examination, Granting | 8585 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2131 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,853
Contact Us
Abstract[English]
Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.[French]
L'invention concerne une autre utilisation médicale du sémaglutide, à savoir le sémaglutide dans le traitement de la claudication intermittente chez un sujet humain atteint de diabète et d'une maladie artérielle périphérique. Le sémaglutide a un impact positif sur les symptômes de la claudication intermittente et, par conséquent, sur la capacité fonctionnelle des membres et la qualité de vie des patients atteints du diabète de type 2 et de la maladie artérielle périphérique.